search
Back to results

Functionality and Neurocognition in Patients With Bipolar Disorder After a Physical-exercise Program (FINEXT-BD Study) (FINEXT-BD)

Primary Purpose

Bipolar Disorder

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Physical exercise
Sponsored by
Bioaraba Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Bipolar Disorder

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with bipolar disorder type I according to the criteria of the DSM-5 manual, diagnosis made by structured interview SCID-P.
  • The study includes patients with first episode and multiple episodes. At the beginning of the study they must be in euthymia, that is, there will be no current diagnosis of manic, hypomanic or depressive episode. Relapses during follow-up and the presence of subindromial symptoms at any time will not result in exclusion from the study.
  • Patients may be treated with any treatment according to clinical guidelines.
  • Age: 18-65 years
  • Speak Spanish correctly
  • Informed consent for the study of the patient

Exclusion Criteria:

  • Presence of organic diseases of the central nervous system (CNS) or history of head trauma with loss of consciousness
  • Intellectual disability.
  • Acute inflammatory disease
  • Treatment with anti-inflammatory drugs during the week prior to sample taking
  • Pervasive developmental disorders.
  • Pregnancy and lactation

Sites / Locations

  • Araba University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control (TAU)

PE intervention+TAU

Arm Description

patients without any intervention + treatment as usual (TAU)

Physical exercise (PE) intervention + treatment as usual (TAU)

Outcomes

Primary Outcome Measures

Patient Functionality measured through the scale FAST (4 months)
The Functioning Assessment Short Test is a brief instrument designed to assess functional impairment in severe mental disorders. The 24 items of the scale cover six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time.
Patient Functionality measured through the scale FAST (10 months)
The Functioning Assessment Short Test is a brief instrument designed to assess functional impairment in severe mental disorders. The 24 items of the scale cover six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time.
Patient Functionality measured through the scale GAF (4 months)
Global Assessment of Functioning (GAF):This scale evaluates with a score from 0 to 100 the level of functioning and the severity of the patient's symptoms, the higher values corresponding to better overall functionality.
Patient Functionality measured through the scale GAF (10 months)
Global Assessment of Functioning (GAF):This scale evaluates with a score from 0 to 100 the level of functioning and the severity of the patient's symptoms, the higher values corresponding to better overall functionality.
Patient Functionality measured through the Strauss-Carpenter scale (4 months)
Strauss-Carpenter scale consists of four items rated from 0 to 4 on a Likert-type scale and yields a total score that is calculated by the addition of all item scores: the higher the score, the better is the prognosis.
Patient Functionality measured through the Strauss-Carpenter scale (10) months)
Strauss-Carpenter scale consists of four items rated from 0 to 4 on a Likert-type scale and yields a total score that is calculated by the addition of all item scores: the higher the score, the better is the prognosis.

Secondary Outcome Measures

TrkB-FL (4 months)
Expression of BDNF: TrkB-FL
TrkB-FL (10 months)
Expression of BDNF: TrkB-FL
TrkB-T (4 months)
Expression of BDNF:TrkB-T
TrkB-T (10 months)
Expression of BDNF:TrkB-T
BDNF (4 months)
Peripheral BDNF levels
BDNF (10 months)
Peripheral BDNF levels
Presence of depressive symptoms (4 months)
Hamilton Depression Scale (HDRS-21)
Presence of depressive symptoms (10 months)
Hamilton Depression Scale (HDRS-21)
VO2Peak in CPET (4 months)
Value of VO2Peak (L min-1) in cardiopulmonary exercise test (CPET)
VO2Peak in CPET (10 months)
Value of VO2Peak (L min-1) in cardiopulmonary exercise test (CPET)
Relative VO2Peak in CPET (4 months)
Value of relative VO2Peak (mL kg-1 min-1) in cardiopulmonary exercise test (CPET)
Relative VO2Peak in CPET (10 months)
Value of relative VO2Peak (mL kg-1 min-1) in cardiopulmonary exercise test (CPET)
METs in CPET (4 months)
Value of metabolic equivalents in cardiopulmonary exercise test (CPET)
METs in CPET (10 months)
Value of metabolic equivalents in cardiopulmonary exercise test (CPET)
VT1 and VT2 in CPET (4 months)
Value of first and second ventilatory threshold (VT1 and VT2)(mL kg-1 min-1) metabolic equivalents in cardiopulmonary exercise test (CPET)
VT1 and VT2 in CPET(10 months)
Value of first and second ventilatory threshold (VT1 and VT2)(mL kg-1 min-1) metabolic equivalents in cardiopulmonary exercise test (CPET)
HRpeak in CPET (4 months)
Value of HRpeak in cardiopulmonary exercise test (CPET)
HRpeak in CPET (10 months)
Value of HRpeak in cardiopulmonary exercise test (CPET)
OCT Study of the retina by optical tomography (4 months)
RFNL, GCL and IPL thickness in the two eyes, with each layer divided into segments: overall, temporal, nasal, superior and inferior.
OCT Study of the retina by optical (10 months)
RFNL, GCL and IPL thickness in the two eyes, with each layer divided into segments: overall, temporal, nasal, superior and inferior.
Muscle mass (4 months)
Anthropometric measures muscle mass (g)
Muscle mass (10 months)
Anthropometric measures muscle mass (g)
Fat mass (%)(4 months)
Anthropometric measures Fat mass (%)
Fat mass (%) (10 months)
Anthropometric measures Fat mass (%)
Bone mineral content (4 months)
Anthropometric measures: Bone mineral density (g/cm^2) shall be determined by Dual Energy X-Ray Absorptiometry (DXA).
Bone mineral content (4 months)
Anthropometric measures: Bone mineral density (g/cm^2) shall be determined by Dual Energy X-Ray Absorptiometry (DXA).
Appendicular muscle mass (4months)
Anthropometric measures: appendicular muscle mass (g) will also be determined by adding up the muscle mass of both arms and legs.
Appendicular muscle mass (10 months)
Anthropometric measures: appendicular muscle mass (g) will also be determined by adding up the muscle mass of both arms and legs.
Oxidative stress (4 months)
Oxidative stress: Total Antioxidant Status (TAS), Glutathione peroxidase (GPx) y - Glutathione (GSH), Lipid Peroxidation (TBARS) y Nitrite (NO2)
Oxidative stress (10 months)
Oxidative stress: Total Antioxidant Status (TAS), Glutathione peroxidase (GPx) y - Glutathione (GSH), Lipid Peroxidation (TBARS) y Nitrite (NO2)
Inflammation (4 months)
Cytokine levels: IL6 and prostaglandin Levels PGE2
Inflammation (10 months)
Cytokine levels: IL6 and prostaglandin Levels PGE2
Manic symptoms using the (YMRS) (4 months)
Young Mania Rating Scale (YMRS): The total score ranges from 0-60, with the status of euthymia being classified as getting 6 or fewer points, hypomania as getting 12 or more points, and mania as getting between 20 and 60 points.
Manic symptoms using the (YMRS) (10 months)
Young Mania Rating Scale (YMRS): The total score ranges from 0-60, with the status of euthymia being classified as getting 6 or fewer points, hypomania as getting 12 or more points, and mania as getting between 20 and 60 points.
Body mass (4 months)
Physical parameters: Body mass (kg)
Body mass (10 months)
Physical parameters: Body mass (kg)
Height (4 months)
Physical parameters: Height (cm)
Height (10 months)
Physical parameters: Height (cm)
BMI (4 months)
Physical parameters: Body mass index (kg/m2)
BMI (10 months)
Physical parameters: Body mass index (kg/m2)
Waist circumference (4 months)
Physical parameters: Waist circumference (cm)
Waist circumference (4 months)
Physical parameters: Waist circumference (cm)
SBP and DBP (4 months)
Physical parameters: Systolic and diastolic blood pressure (mm Hg) measured taken from the right arm in a seated and relaxed position by using a life-support monitor
SBP and DBP (10 months)
Physical parameters: Systolic and diastolic blood pressure (mm Hg) measured taken from the right arm in a seated and relaxed position by using a life-support monitor
TG (4 months)
Physical parameters: Serum levels of triglycerides (mg/dl )
TG (10 months)
Physical parameters: Serum levels of triglycerides (mg/dl )
Glucose (4 months)
Physical parameters: Glucose (mg/dl)
Glucose (10 months)
Physical parameters: Glucose (mg/dl)
HDL (4 months)
Physical parameters: HDL colesterol (mg/dl)
HDL (10 months)
Physical parameters: HDL colesterol (mg/dl)
Patient symptom severity measured through the scale CGI (4 months)
The Clinical Global Impression Scale (CGI): consists of two subscales. Each subscale has a single item scored between 0, not evaluated, to 7 which corresponds to the maximum severity (severity subscale) or to a state of no improvement and aggravated worsening of the symptomatology (improvement subscale).
Patient symptom severity measured through the scale CGI (10 months)
The Clinical Global Impression Scale (CGI): consists of two subscales. Each subscale has a single item scored between 0, not evaluated, to 7 which corresponds to the maximum severity (severity subscale) or to a state of no improvement and aggravated worsening of the symptomatology (improvement subscale).
Cognitive functioning measured through CVLT (10 months)
California Verbal Learning Test
Cognitive functioning measured through CVLT (4 months)
California Verbal Learning Test
Cognitive functioning measured through WSCT (10 months)
Computerized version of Wisconsin Card Sorting Test: This test consists of cards depicting simple geometric figures that vary in color, shape, and number. Examinees must sort cards in accordance with one of three viable rules, i.e., according to the color, shape, or number of the depicted objects
Cognitive functioning measured through WSCT (4 months)
Computerized version of Wisconsin Card Sorting Test: This test consists of cards depicting simple geometric figures that vary in color, shape, and number. Examinees must sort cards in accordance with one of three viable rules, i.e., according to the color, shape, or number of the depicted objects
Cognitive functioning measured through (SCWT) (10 months)
The Stroop Color and Word Test: Individuals are required to read three different tables as fast as possible. Two of them represent the "congruous condition" in which participants are required to read names of colors (color-words) printed in black ink (W) and name different color patches (C). Conversely, in the third table, named color-word (CW) condition, color-words are printed in an inconsistent color ink.
Cognitive functioning measured through (SCWT) (4 months)
The Stroop Color and Word Test: Individuals are required to read three different tables as fast as possible. Two of them represent the "congruous condition" in which participants are required to read names of colors (color-words) printed in black ink (W) and name different color patches (C). Conversely, in the third table, named color-word (CW) condition, color-words are printed in an inconsistent color ink.

Full Information

First Posted
May 11, 2020
Last Updated
September 14, 2020
Sponsor
Bioaraba Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04400630
Brief Title
Functionality and Neurocognition in Patients With Bipolar Disorder After a Physical-exercise Program (FINEXT-BD Study)
Acronym
FINEXT-BD
Official Title
Functionality and Neurocognition in Patients With Bipolar Disorder After a Physical-exercise Program (FINEXT-BD Study): Protocol of a Randomized Interventionist Program
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
November 5, 2019 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bioaraba Health Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a study that aimed to deep in the physiopathology of BD and see how, through potential modifiable areas of the patients' lifestyle, the prognosis and evolution of the pathology can be improved.
Detailed Description
Randomized interventionist study (ratio 1:1) with two parallel branches, blinded by evaluators (the evaluator does not know the branch of treatment to which the patient belongs )to evaluate if an individualized moderate-to-vigorous physical exercise intensity program as adjuvant therapy to standard drug therapy will improve the functional and neuropsychological status of patients with Bipolar Disorder. The effectiveness of the intervention will be assessed by an extensive battery of clinical tests, physical parameters (e.g. brain structure changes measured by optical coherence tomography) and biological parameters (inflammation, oxidative stress and neurotrophic factors). The total sample of the study will be 80 patients and a sample of 40 controls (individuals without psychiatric pathology). The sample of patients will be divided into 40 patients in each group at random. In the intervention group, a supervised physical exercise treatment by high-intensity interval training (HIT) will be performed during 16 weeks with 2 sessions per week (32 sessions in total).Three visits will be made in both groups: baseline visit at the beginning of the study, at 4 months (at the end of the intervention) and at 10 months (6 months after the end of the intervention)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Longitudinal, interventional, randomized, controlled, simple-blind clinical trial
Masking
Investigator
Masking Description
The person in charge of the assessments will not be involved in the treatment program and will be blinded to this process. Study evaluators will be blinded to the treatment branch
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control (TAU)
Arm Type
No Intervention
Arm Description
patients without any intervention + treatment as usual (TAU)
Arm Title
PE intervention+TAU
Arm Type
Experimental
Arm Description
Physical exercise (PE) intervention + treatment as usual (TAU)
Intervention Type
Other
Intervention Name(s)
Physical exercise
Intervention Description
The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
Primary Outcome Measure Information:
Title
Patient Functionality measured through the scale FAST (4 months)
Description
The Functioning Assessment Short Test is a brief instrument designed to assess functional impairment in severe mental disorders. The 24 items of the scale cover six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time.
Time Frame
Change at the end of the training period (4 months)
Title
Patient Functionality measured through the scale FAST (10 months)
Description
The Functioning Assessment Short Test is a brief instrument designed to assess functional impairment in severe mental disorders. The 24 items of the scale cover six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time.
Time Frame
Changes after 10 months
Title
Patient Functionality measured through the scale GAF (4 months)
Description
Global Assessment of Functioning (GAF):This scale evaluates with a score from 0 to 100 the level of functioning and the severity of the patient's symptoms, the higher values corresponding to better overall functionality.
Time Frame
Change at the end of the training period (4 months)
Title
Patient Functionality measured through the scale GAF (10 months)
Description
Global Assessment of Functioning (GAF):This scale evaluates with a score from 0 to 100 the level of functioning and the severity of the patient's symptoms, the higher values corresponding to better overall functionality.
Time Frame
Changes after 10 months
Title
Patient Functionality measured through the Strauss-Carpenter scale (4 months)
Description
Strauss-Carpenter scale consists of four items rated from 0 to 4 on a Likert-type scale and yields a total score that is calculated by the addition of all item scores: the higher the score, the better is the prognosis.
Time Frame
Change at the end of the training period (4 months)
Title
Patient Functionality measured through the Strauss-Carpenter scale (10) months)
Description
Strauss-Carpenter scale consists of four items rated from 0 to 4 on a Likert-type scale and yields a total score that is calculated by the addition of all item scores: the higher the score, the better is the prognosis.
Time Frame
Changes after 10 months
Secondary Outcome Measure Information:
Title
TrkB-FL (4 months)
Description
Expression of BDNF: TrkB-FL
Time Frame
Change at the end of the training period (4 months)
Title
TrkB-FL (10 months)
Description
Expression of BDNF: TrkB-FL
Time Frame
Changes after 10 months
Title
TrkB-T (4 months)
Description
Expression of BDNF:TrkB-T
Time Frame
Change at the end of the training period (4 months)
Title
TrkB-T (10 months)
Description
Expression of BDNF:TrkB-T
Time Frame
Changes after 10 months
Title
BDNF (4 months)
Description
Peripheral BDNF levels
Time Frame
Change at the end of the training period (4 months)
Title
BDNF (10 months)
Description
Peripheral BDNF levels
Time Frame
Changes after 10 months
Title
Presence of depressive symptoms (4 months)
Description
Hamilton Depression Scale (HDRS-21)
Time Frame
Change at the end of the training period (4 months)
Title
Presence of depressive symptoms (10 months)
Description
Hamilton Depression Scale (HDRS-21)
Time Frame
Changes after 10 months
Title
VO2Peak in CPET (4 months)
Description
Value of VO2Peak (L min-1) in cardiopulmonary exercise test (CPET)
Time Frame
Change at the end of the training period (4 months)
Title
VO2Peak in CPET (10 months)
Description
Value of VO2Peak (L min-1) in cardiopulmonary exercise test (CPET)
Time Frame
Changes after 10 months
Title
Relative VO2Peak in CPET (4 months)
Description
Value of relative VO2Peak (mL kg-1 min-1) in cardiopulmonary exercise test (CPET)
Time Frame
Change at the end of the training period (4 months)
Title
Relative VO2Peak in CPET (10 months)
Description
Value of relative VO2Peak (mL kg-1 min-1) in cardiopulmonary exercise test (CPET)
Time Frame
Changes after 10 months
Title
METs in CPET (4 months)
Description
Value of metabolic equivalents in cardiopulmonary exercise test (CPET)
Time Frame
Change at the end of the training period (4 months)
Title
METs in CPET (10 months)
Description
Value of metabolic equivalents in cardiopulmonary exercise test (CPET)
Time Frame
Changes after 10 months
Title
VT1 and VT2 in CPET (4 months)
Description
Value of first and second ventilatory threshold (VT1 and VT2)(mL kg-1 min-1) metabolic equivalents in cardiopulmonary exercise test (CPET)
Time Frame
Change at the end of the training period (4 months)
Title
VT1 and VT2 in CPET(10 months)
Description
Value of first and second ventilatory threshold (VT1 and VT2)(mL kg-1 min-1) metabolic equivalents in cardiopulmonary exercise test (CPET)
Time Frame
Changes after 10 months
Title
HRpeak in CPET (4 months)
Description
Value of HRpeak in cardiopulmonary exercise test (CPET)
Time Frame
Change at the end of the training period (4 months)
Title
HRpeak in CPET (10 months)
Description
Value of HRpeak in cardiopulmonary exercise test (CPET)
Time Frame
Changes after 10 months
Title
OCT Study of the retina by optical tomography (4 months)
Description
RFNL, GCL and IPL thickness in the two eyes, with each layer divided into segments: overall, temporal, nasal, superior and inferior.
Time Frame
Change at the end of the training period (4 months)
Title
OCT Study of the retina by optical (10 months)
Description
RFNL, GCL and IPL thickness in the two eyes, with each layer divided into segments: overall, temporal, nasal, superior and inferior.
Time Frame
Changes after 10 months
Title
Muscle mass (4 months)
Description
Anthropometric measures muscle mass (g)
Time Frame
Change at the end of the training period (4 months)
Title
Muscle mass (10 months)
Description
Anthropometric measures muscle mass (g)
Time Frame
Changes after 10 months
Title
Fat mass (%)(4 months)
Description
Anthropometric measures Fat mass (%)
Time Frame
Change at the end of the training period (4 months)
Title
Fat mass (%) (10 months)
Description
Anthropometric measures Fat mass (%)
Time Frame
Changes after 10 months
Title
Bone mineral content (4 months)
Description
Anthropometric measures: Bone mineral density (g/cm^2) shall be determined by Dual Energy X-Ray Absorptiometry (DXA).
Time Frame
Change at the end of the training period (4 months)
Title
Bone mineral content (4 months)
Description
Anthropometric measures: Bone mineral density (g/cm^2) shall be determined by Dual Energy X-Ray Absorptiometry (DXA).
Time Frame
Changes after 10 months
Title
Appendicular muscle mass (4months)
Description
Anthropometric measures: appendicular muscle mass (g) will also be determined by adding up the muscle mass of both arms and legs.
Time Frame
Change at the end of the training period (4 months)
Title
Appendicular muscle mass (10 months)
Description
Anthropometric measures: appendicular muscle mass (g) will also be determined by adding up the muscle mass of both arms and legs.
Time Frame
Changes after 10 months
Title
Oxidative stress (4 months)
Description
Oxidative stress: Total Antioxidant Status (TAS), Glutathione peroxidase (GPx) y - Glutathione (GSH), Lipid Peroxidation (TBARS) y Nitrite (NO2)
Time Frame
Change at the end of the training period (4 months)
Title
Oxidative stress (10 months)
Description
Oxidative stress: Total Antioxidant Status (TAS), Glutathione peroxidase (GPx) y - Glutathione (GSH), Lipid Peroxidation (TBARS) y Nitrite (NO2)
Time Frame
Changes after 10 months
Title
Inflammation (4 months)
Description
Cytokine levels: IL6 and prostaglandin Levels PGE2
Time Frame
Change at the end of the training period (4 months)
Title
Inflammation (10 months)
Description
Cytokine levels: IL6 and prostaglandin Levels PGE2
Time Frame
Changes after 10 months
Title
Manic symptoms using the (YMRS) (4 months)
Description
Young Mania Rating Scale (YMRS): The total score ranges from 0-60, with the status of euthymia being classified as getting 6 or fewer points, hypomania as getting 12 or more points, and mania as getting between 20 and 60 points.
Time Frame
Change at the end of the training period (4 months)
Title
Manic symptoms using the (YMRS) (10 months)
Description
Young Mania Rating Scale (YMRS): The total score ranges from 0-60, with the status of euthymia being classified as getting 6 or fewer points, hypomania as getting 12 or more points, and mania as getting between 20 and 60 points.
Time Frame
Changes after 10 months
Title
Body mass (4 months)
Description
Physical parameters: Body mass (kg)
Time Frame
Change at the end of the training period (4 months)
Title
Body mass (10 months)
Description
Physical parameters: Body mass (kg)
Time Frame
Changes after 10 months
Title
Height (4 months)
Description
Physical parameters: Height (cm)
Time Frame
Change at the end of the training period (4 months)
Title
Height (10 months)
Description
Physical parameters: Height (cm)
Time Frame
Changes after 10 months
Title
BMI (4 months)
Description
Physical parameters: Body mass index (kg/m2)
Time Frame
Change at the end of the training period (4 months)
Title
BMI (10 months)
Description
Physical parameters: Body mass index (kg/m2)
Time Frame
Changes after 10 months
Title
Waist circumference (4 months)
Description
Physical parameters: Waist circumference (cm)
Time Frame
Change at the end of the training period (4 months)
Title
Waist circumference (4 months)
Description
Physical parameters: Waist circumference (cm)
Time Frame
Changes after 10 months
Title
SBP and DBP (4 months)
Description
Physical parameters: Systolic and diastolic blood pressure (mm Hg) measured taken from the right arm in a seated and relaxed position by using a life-support monitor
Time Frame
Change at the end of the training period (4 months)
Title
SBP and DBP (10 months)
Description
Physical parameters: Systolic and diastolic blood pressure (mm Hg) measured taken from the right arm in a seated and relaxed position by using a life-support monitor
Time Frame
Changes after 10 months
Title
TG (4 months)
Description
Physical parameters: Serum levels of triglycerides (mg/dl )
Time Frame
Change at the end of the training period (4 months)
Title
TG (10 months)
Description
Physical parameters: Serum levels of triglycerides (mg/dl )
Time Frame
Changes after 10 months
Title
Glucose (4 months)
Description
Physical parameters: Glucose (mg/dl)
Time Frame
Change at the end of the training period (4 months)
Title
Glucose (10 months)
Description
Physical parameters: Glucose (mg/dl)
Time Frame
Changes after 10 months
Title
HDL (4 months)
Description
Physical parameters: HDL colesterol (mg/dl)
Time Frame
Change at the end of the training period (4 months)
Title
HDL (10 months)
Description
Physical parameters: HDL colesterol (mg/dl)
Time Frame
Changes after 10 months
Title
Patient symptom severity measured through the scale CGI (4 months)
Description
The Clinical Global Impression Scale (CGI): consists of two subscales. Each subscale has a single item scored between 0, not evaluated, to 7 which corresponds to the maximum severity (severity subscale) or to a state of no improvement and aggravated worsening of the symptomatology (improvement subscale).
Time Frame
Change at the end of the training period (4 months)
Title
Patient symptom severity measured through the scale CGI (10 months)
Description
The Clinical Global Impression Scale (CGI): consists of two subscales. Each subscale has a single item scored between 0, not evaluated, to 7 which corresponds to the maximum severity (severity subscale) or to a state of no improvement and aggravated worsening of the symptomatology (improvement subscale).
Time Frame
Changes after 10 months
Title
Cognitive functioning measured through CVLT (10 months)
Description
California Verbal Learning Test
Time Frame
Changes after 10 months
Title
Cognitive functioning measured through CVLT (4 months)
Description
California Verbal Learning Test
Time Frame
Change at the end of the training period (4 months)
Title
Cognitive functioning measured through WSCT (10 months)
Description
Computerized version of Wisconsin Card Sorting Test: This test consists of cards depicting simple geometric figures that vary in color, shape, and number. Examinees must sort cards in accordance with one of three viable rules, i.e., according to the color, shape, or number of the depicted objects
Time Frame
Changes after 10 months
Title
Cognitive functioning measured through WSCT (4 months)
Description
Computerized version of Wisconsin Card Sorting Test: This test consists of cards depicting simple geometric figures that vary in color, shape, and number. Examinees must sort cards in accordance with one of three viable rules, i.e., according to the color, shape, or number of the depicted objects
Time Frame
Change at the end of the training period (4 months)
Title
Cognitive functioning measured through (SCWT) (10 months)
Description
The Stroop Color and Word Test: Individuals are required to read three different tables as fast as possible. Two of them represent the "congruous condition" in which participants are required to read names of colors (color-words) printed in black ink (W) and name different color patches (C). Conversely, in the third table, named color-word (CW) condition, color-words are printed in an inconsistent color ink.
Time Frame
Changes after 10 months
Title
Cognitive functioning measured through (SCWT) (4 months)
Description
The Stroop Color and Word Test: Individuals are required to read three different tables as fast as possible. Two of them represent the "congruous condition" in which participants are required to read names of colors (color-words) printed in black ink (W) and name different color patches (C). Conversely, in the third table, named color-word (CW) condition, color-words are printed in an inconsistent color ink.
Time Frame
Change at the end of the training period (4 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with bipolar disorder type I according to the criteria of the DSM-5 manual, diagnosis made by structured interview SCID-P. The study includes patients with first episode and multiple episodes. At the beginning of the study they must be in euthymia, that is, there will be no current diagnosis of manic, hypomanic or depressive episode. Relapses during follow-up and the presence of subindromial symptoms at any time will not result in exclusion from the study. Patients may be treated with any treatment according to clinical guidelines. Age: 18-65 years Speak Spanish correctly Informed consent for the study of the patient Exclusion Criteria: Presence of organic diseases of the central nervous system (CNS) or history of head trauma with loss of consciousness Intellectual disability. Acute inflammatory disease Treatment with anti-inflammatory drugs during the week prior to sample taking Pervasive developmental disorders. Pregnancy and lactation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ana María Gonzalez-Pinto
Phone
+34 945007879
Email
anapinto@telefonica.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ana María Gonzalez-Pinto
Organizational Affiliation
BIOARABA HRI
Official's Role
Principal Investigator
Facility Information:
Facility Name
Araba University Hospital
City
Vitoria
State/Province
Alava
ZIP/Postal Code
01009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana María Gonzalez-Pinto
Phone
+34 945007879
Email
anapinto@telefonica.net

12. IPD Sharing Statement

Citations:
PubMed Identifier
33240125
Citation
Garcia S, Gorostegi-Anduaga I, Garcia-Corres E, Maldonado-Martin S, MacDowell KS, Bermudez-Ampudia C, Apodaca MJ, Perez-Landaluce I, Tobalina-Larrea I, Leza JC, Gonzalez-Pinto A. Functionality and Neurocognition in Patients With Bipolar Disorder After a Physical-Exercise Program (FINEXT-BD Study): Protocol of a Randomized Interventionist Program. Front Psychiatry. 2020 Oct 29;11:568455. doi: 10.3389/fpsyt.2020.568455. eCollection 2020.
Results Reference
derived

Learn more about this trial

Functionality and Neurocognition in Patients With Bipolar Disorder After a Physical-exercise Program (FINEXT-BD Study)

We'll reach out to this number within 24 hrs